Resources for You
Nexium (esomeprazole sodium) for Intravenous Injection, Delayed-Release Capsules, and Delayed-Release Oral Suspension
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)
WARNINGS AND PRECAUTIONS
Interactions with Diagnostic Investigations for Neuroendocrine Tumors
- Healthcare providers should temporarily stop omeprazole treatment at least 14 days before assessing CgA levels and consider repeating the test if initial CgA levels are high. If serial tests are performed (e.g. for monitoring), the same commercial laboratory should be used for testing, as reference ranges between tests may vary.